QuidelOrtho (QDEL) announced it has completed the acquisition of LEX Diagnostics for cash consideration of approximately $100M. The LEX VELO System received U.S. FDA 510(k) clearance and CLIA waiver in February 2026. QuidelOrtho expects to initiate the U.S. commercial launch of the LEX VELO System later this year. Global expansion is expected to follow, subject to local regulatory approvals.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QDEL:
- Midday Fly By: PepsiCo reports mixed Q1, TSMC reports Q1 beat
- Morning Movers: Hims & Hers jumps as FDA looks to broader peptide access
- Video: PepsiCo rises as sales and earnings beat expectations
- Closing Bell Movers: JB Hunt up 2% after Q1 earnings beat
- QuidelOrtho falls 12% to $15.25 after Q1 revenue guidance misses estimates